INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 66 filers reported holding INFINITY PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.62 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $445,000 | +49.3% | 219,652 | -2.3% | 0.03% | +65.0% |
| Q3 2017 | $298,000 | -17.9% | 224,793 | -2.8% | 0.02% | -23.1% |
| Q2 2017 | $363,000 | -58.4% | 231,293 | -14.5% | 0.03% | -57.4% |
| Q1 2017 | $873,000 | +139.2% | 270,417 | -0.1% | 0.06% | +144.0% |
| Q4 2016 | $365,000 | -31.4% | 270,749 | -20.6% | 0.02% | -34.2% |
| Q3 2016 | $532,000 | +15.9% | 341,090 | -1.3% | 0.04% | +18.8% |
| Q2 2016 | $459,000 | -75.2% | 345,446 | -1.8% | 0.03% | -74.2% |
| Q1 2016 | $1,853,000 | +30.8% | 351,789 | +94.8% | 0.12% | +21.6% |
| Q4 2015 | $1,417,000 | -64.2% | 180,609 | -61.5% | 0.10% | -63.7% |
| Q3 2015 | $3,963,000 | +556.1% | 469,045 | +749.3% | 0.28% | +524.4% |
| Q2 2015 | $604,000 | -90.6% | 55,224 | -88.0% | 0.04% | -89.9% |
| Q1 2015 | $6,457,000 | -17.2% | 461,902 | 0.0% | 0.44% | -14.1% |
| Q4 2014 | $7,801,000 | +24.4% | 461,902 | -1.2% | 0.52% | +27.3% |
| Q3 2014 | $6,273,000 | – | 467,491 | – | 0.41% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
| Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
| QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
| BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
| Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
| Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
| Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
| OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
| Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |